1430321-42-8

Basic information

• Product Name: 1-(2-fluoro-4-nitrophenyl)-4,4-dimethyl-1,4-azasilinane
• Synonyms: 1-(2-fluoro-4-nitrophenyl)-4,4-dimethyl-1,4-azasilinane
• CAS NO: 1430321-42-8
• Molecular Weight: 268.363
• Mol File: 1430321-42-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1-(2-fluoro-4-nitrophenyl)-4,4-dimethyl-1,4-azasilinane(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-fluoro-4-nitrophenyl)-4,4-dimethyl-1,4-azasilinane(1430321-42-8)
• EPA Substance Registry System: 1-(2-fluoro-4-nitrophenyl)-4,4-dimethyl-1,4-azasilinane(1430321-42-8)

Safety Data

• Hazardous Substances Data: 1430321-42-8(Hazardous Substances Data)

Upstream product

• 10519-87-6 divinyldimethylsilane 
• 51664-50-7 dimethylbis(2-bromoethyl)silane 
• 130596-60-0 1-benzyl-4,4-dimethyl-1,4-azasilinane 
• 130596-62-2 4,4-dimethyl-4-silapiperidine hydrochloride 
• 369-34-6 3,4-difluoronitrobenzene 

Downstream Products

• 1430321-43-9 benzyl 4-(4,4-dimethyl-1,4-azasilinan-1-yl)-3-fluorophenylcarbamate 
• 1430321-45-1 (S)-N-((3-(4-(4,4-dimethyl-1,4-azasilinan-1-yl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide 
• 1430321-44-0 (S)-5-(aminoniethyl)-3-(4-(4,4-dimethyl-1,4-azasilinan-1-yl)-3-fluorophenyl)oxazolidin-2-one 
• 1430321-46-2 (S)-N-((3-(4-(4,4-dimethyl-1,4-azasilinan-1-yl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)propionamide 
• 1430321-47-3 (S)-methyl ((3-(4-(4,4-dimethyl-1,4-azasilinan-1-yl)-3-fluorophenyl)-2-oxooxazolidin-5-yl) methyl)carbamate 
• 1430321-48-4 (S)-O-methyl ((3-(4-(4,4-dimethyl-1,4-azasilinan-1-yl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)carbamothioate 
• 1430321-49-5 (R)-3-(4-(4,4-dimethyl-1,4-azasilinan-1-yl)-3-fluorophenyl)-5-(hydroxymethyl)oxazolidin-2-one 
• 1430321-50-8 (R)-(3-(4-(4,4-dimethyl-1,4-azasilinan-1-yl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl methanesulfonate 
• 1430321-51-9 (R)-5-(azidomethyl)-3-(4-(4,4-dimethyl-1,4-azasilinan-1-yl)-3-fluorophenyl)oxazolidin-2-one 
• 1430321-52-0 (R)-5-((1H-1,2,3-triazol-1-yl)methyl)-3-(4-(4,4-dimethyl-1,4-azasilinan-1-yl)-3-fluorophenyl)oxazolidin-2-one 

Relevant articles and documents

Discovery of a Silicon-Containing Pan-Genotype Hepatitis C Virus NS5A Inhibitor

We describe a study leading to the discovery of compound 11, a pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with excellent potency, metabolic stability, and pharmacokinetics (PK). Compound 11 incorporating a 4-silapiperidine group was discovered by further optimizing our previous lead with a triethylsilyl moiety. It displayed great potency against genotype 1 subtype a (GT1a), -1b, -2a, -3a, -4a, -5a, and -6a with an EC50 range of 0.33-17 pM and improved potency against the resistance-associated variant GT1a-M28T. Pharmacokinetics (PK) study indicated that compound 11 has reasonable PK exposures with a high liver distribution in preclinical animal species (mouse, rat, and dog). The results of a 14 day repeat-dose toxicity study identified the safety of compound 11.

Design, Synthesis, and Identification of Silicon Incorporated Oxazolidinone Antibiotics with Improved Brain Exposure

Therapeutic options for brain infections caused by pathogens with a reduced sensitivity to drugs are limited. Recent reports on the potential use of linezolid in treating brain infections prompted us to design novel compounds around this scaffold. Herein, we describe the design and synthesis of various oxazolidinone antibiotics with the incorporation of silicon. Our findings in preclinical species suggest that silicon incorporation is highly useful in improving brain exposures. Interestingly, three compounds from this series demonstrated up to a 30-fold higher brain/plasma ratio when compared to linezolid thereby indicating their therapeutic potential in brain associated disorders.

SILA ANALOGS OF OXAZOLIDINONE DERIVATIVES AND SYNTHESIS THEREOF

The invention discloses silaanalogs of oxazolidinone compounds, to pharmaceutical compositions and to the synthesis of the oxazolidinone derivatives of formula I. The invention further relates to methods of treating a subject suffering with gram positive pathogens including those resistant to methicillin and vancomycin using the compound(s) or modulation of coagulation properties of blood-clotting cascade or compositions of the oxazolidinone derivatives of the invention.